Compare Inovio Pharmaceuticals Inc (INO) vs iShares Silver Trust (SLV) Price & Performance

INO trades at $0.9001, up 17.54% in the last session, but the technical outlook is bearish with key indicators like the 6-day RSI at 73.22 signaling overbought conditions. Fundamentally, the company reports minimal revenue of $65,340 in 2025 against a net loss of $84.95 million, reflecting a net income margin of -130,000%. Recent news highlights FDA review progress for INO-3107, with a PDUFA date set for October 30, 2026, representing a critical near-term catalyst.

The investment case hinges on the binary FDA decision for INO-3107, with a consensus price target of $3.25 implying significant upside if approved. However, high cash burn, persistent losses, and a bearish technical setup present substantial risks. Analyst sentiment is mixed with a 52.95% buy rating, but the stock remains a high-risk, event-driven play.

SLV (iShares Silver Trust) trades at $59.06, up 0.87% with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides direct exposure to physical silver, benefiting from structural supply deficits and growing industrial demand, particularly from data centers. Recent news highlights silver's rebound after a 50% correction from early 2026 highs, with analysts noting improved risk-reward profiles.

Silver's outlook remains compelling due to constrained supply and robust demand, though the ETF faces volatility risks from Fed policy shifts and dollar strength. Current technical levels show support at $58-59 and resistance at $60-61, with the ADX indicating strong trend momentum despite overbought conditions.